… a business update and reported financial results for the quarter ended September … experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep … business strategy. Third Quarter 2025 Financial Results Cash Position: Cash and cash …

… under its license agreement with Gilead Sciences, Inc. (Gilead). For more information, … in 2027. Third Quarter 2025 Financial Results Collaboration and License Revenue: … exclusive global license agreement with Gilead to develop and commercialize …

… partnering proceeds from Sanofi and Gilead Granted license to additional … MacroGenics’ Financial Position Gilead. In November 2025, Gilead licensed an additional … to TZIELD. Third Quarter 2025 Financial Results Cash Position: Cash, cash equivalents …

… medicines for patients, today reported financial results for the quarter ended September … positions with Kite Pharma / Gilead, Sanofi and Amgen, and having … Board Chair. Third Quarter 2025 Financial Results Cash Position: Cash, cash equivalents …

… ABI-1179 was contributed by Gilead Sciences, Inc. (Gilead) under the collaboration between … been established. Third Quarter 2025 Financial Results Cash, cash equivalents and marketable … Assembly Bio’s collaboration with Gilead, in the currently anticipated …

… our shareholders.” Third Quarter 2025 Financial Results Total revenues and other income … Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more … and guidance regarding projected 2025 financial results. Actual events or results may …

… exclusive access rights granted to Gilead for Galapagos’ drug discovery platform … limited to, statements regarding our financial results, including statements regarding the expected … limited to, our collaboration partners Gilead, Lonza and USWorldMeds), the …

… cancer medicines, today reported financial results for the third quarter ended … -extension payments under the Gilead collaboration were recognized as … all ongoing work at Gilead on licensed programs will … drug discovery program to Gilead for $12.0 million …

… and license agreement with Gilead Sciences to advance the Company… and intellectual property functions. Financial Results Collaboration Revenues: Collaboration revenues … Company’s collaboration with Gilead Sciences. Collaboration revenues recognized in …

… quot; Third Quarter 2025 Financial Results Total third quarter 2025 … the accompanying tables. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical … business, including the following: GILEAD®, Gilead Sciences®, KITE®, AMBISOME®, ATRIPLA®, …